ResMed share price drops: Is this a buying opportunity?

Is it time to buy ResMed shares?

| More on:
A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price is trading lower on Thursday.

In afternoon trade, the sleep treatment focused medical device company's shares are down 1.5% to $33.78.

Why is the ResMed share price falling?

The weakness in the ResMed share price could have been driven by the release of an update from one of one of the company's rivals.

Overnight, health technology giant Philips revealed that its third-quarter financial performance was impacted by continued supply chain challenges that were more significant than anticipated.

It also warned that the remainder of the second half may not be as strong as expected because of these challenges. The company said:

Looking ahead, Philips still expects a better second half of the year, compared to the first half of 2022. However, the company sees prolonged supply chain disruptions and a worsening macro-environment. Consequently, Philips now expects a mid-single-digit comparable sales decline for the fourth quarter of 2022 with a high-single-to-double-digit adjusted EBITA margin range.

Is this a buying opportunity?

According to a note out of Goldman Sachs, its analysts remain bullish on the ResMed share price.

This morning the broker has retained its buy rating and $36.80 price target on the company's shares.

Based on where its shares are trading today, this implies potential upside of 9% for investors over the next 12 months. It commented:

We are Buy-rated on RMD. Our 12-month target price of A$36.80 is unchanged and remains based 85% on our NTM EV/EBITDA valuation of A$35.00 (multiple of 27.3x based on weighted average of peers, sector and DCF target multiple) and 15% on our M&A valuation of A$46.90 (multiple of 36.7x).

Goldman also remains neutral on fellow medical device company Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), with a price target of $17.90.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »